Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis

Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis

Purpose: Recently, the U.S. Food and Drug Administration (FDA) approved stiripentol, cannabidiol, and fenfluramine to treat patients with Dravet syndrome (DS). Moreover, soticlestat was determined as a promising new drug for the treatment of DS as it has good efficacy and safety. However, the effica...

Full description

Bibliographic Details
Main Authors: Jianhua Wu, Liu Zhang, Xi Zhou, Jiajun Wang, Xiangyi Zheng, Hankun Hu, Dongfang Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
soticlestat
stiripentol
fenfluramine
cannabidiol
dravet syndrome
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.980937/full

Similar Items

Similar Items